secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-04-24T23:59:59+00:00
Accession:  0001193125-26-177406
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma CAO Louise Kooij to depart Aug 31, 2026; severance terms set
--------------------------------------------------------------------------------

- Louise Kooij to step down as Chief Accounting Officer effective August 31, 2026.
- Separation agreement includes 12 months base salary lump sum and pro-rated 2026 bonus.
- Vesting of outstanding stock options and RSUs extended to Jan 10, 2027; exercise period to Feb 10, 2027.
- Agreement includes confidentiality, non-compete, non-disparagement covenants and claims release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526177406/0001193125-26-177406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526177406/nams-20260420.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-177406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer